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Retrospective Case Series of Aripiprazole Augmentation  
in Pervasive Developmental Disorders
Yeni Kim*, Soo-Churl Cho, Min-Sup Shin, Jae-Won Kim, Seung-Hee Lee† and Boong-Nyun Kim
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Due to co-morbidities and treatment resistant nature of pervasive developmental disorder (PDD), diverse combinations of regimens have 
been tried. This retrospective study aimed to explore adjunctive use of aripiprazole in children with PDD. Changes in illness severity were 
measured by Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Improvement (CGI-I) in 14 aripiprazole-
treated patients with PDD. Improvement of illness severity was observed after aripiprazole add-on (5.8±0.8 to 4.9±1.0, Z=-2.75, p=0.001). 
Mean dosage was 7.7 mg/day [standard deviation (SD) 3.3, range 5-15]. A higher mean dosage was observed in group with improvement 
in symptoms (t=-2.33, df =12, p=0.004). The target symptoms most effectively improved after using aripiprazole were positive psychotic 
symptoms (mean CGI-I: 2.0±1.4, 3 responders/4 patients, 75% response) followed by aggressive behavior (2.5±1.7, 3/4, 75%), self-injuri-
ous behavior (2.0±1.0, 2/3, 67%), stereotypic behavior (2.7±1.2, 2/3, 67%), tic (2.8±1.0, 2/4, 50%), irritability (3.5±2.1, 1/2, 50%), obsessive 
behavior (2.5±2.1, 1/3, 33%), hyperactivity (3.4±1.6, 3/7, 43%) and mood fluctuation (3, 0/1, no response). Five patients (35%) discontin-
ued aripiprazole due to treatment-emergent adverse effects (akathisia, insomnia, withdrawal). The results of this study suggest that aripip-
razole augmentation may be used safely in maladaptive behaviors of some populations of PDD. However, future studies are required to con-
firm these preliminary findings.  Psychiatry Investig 2010;7:220-223
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INTRODUCTION
Pervasive developmental disorder (PDD) is a challenging psy-
chiatric condition characterized by impairment in social inter-
actions, deficits in communication and challenges with stereo-
typic behaviors.
1 Children with PDD often display severe mal-
adaptive behaviors, including aggression, hyperactivity, and dif-
ficulties with eating and sleeping.
1 Although, no specific phar-
macologic treatment exists for the core symptoms of PDD, me-
dication serves as one of the mainstays of treatment in ameliorat-
ing the associated maladaptive behavioral symptoms of PDD.
1
Aripiprazole is a novel antipsychotic, which shows partial ago-
nist effects at D2 and serotonin 5-HT1A receptors.
2 Aripipra-
zole was associated with a better metabolic profile compared 
to previous antipsychotics. A randomized control trial in chil-
dren and adolescents with schizophrenia,
3 reported no signif-
icant increase in weight, body mass index or other metabolic 
parameters including cholesterol, fasting glucose, triglycerides, 
and one open label trial reported a significant weight loss when 
changing from other atypical antipsychotics to aripiprazole.
4
With its unique receptor profile, aripiprazole is being tried as 
augmentation for variety of treatment refractory psychiatric con-
ditions.
5 In this study, we report a retrospective case series of 
aripiprazole-treated PDD patients receiving other psychotro-
pic medications in a homogenous sample of Asian ethnicity.
METHODS
Patient records from the Child and Adolescent Psychiatric 
Unit at Seoul National University Children’s Hospital from 
April 2004 to December 2007 were reviewed. Fourteen patients 
diagnosed with autism, Asperger’s disorder or PDD according 
to DSM-IV criteria were identified as receiving aripiprazole 
augmentation therapy. 
Baseline and endpoint measures of the total illness severity 
were assessed by the Clinical Global Impression of Severity 
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of Illness (CGI-S) score. Improvement in target symptoms, fo-
cusing on aggression, self-injury, stereotypy, tics, obsessive be-
havior, and hyperactivity, were determined by the Clinical Glo-
bal Impression of Improvement (CGI-I). Patients showing the 
endpoint CGI-I rating of 1 or 2 were considered “responders”. 
Two independent board-certified psychiatrists (C.S.C and L.S.H) 
with good inter-rater reliability (ĸ=0.84) conducted the CGIs 
on all patients and were blind to each other’s ratings. A third 
psychiatrist (Y.N.K) compared the two ratings. Tolerability of 
aripiprazole augmentation was assessed by documented ad-
verse events. Wilcoxon’s signed-rank test, Fisher’s exact test and 
Student’s t-test were used to analyze the data. All tests were 2- 
tailed and statistical significance was set at 0.05. The study pro-
tocol was approved by the Institutional Review Board.
RESULTS 
Participants
The demographic and clinical data of each patient are listed 
in Table 1. The mean age was 12.1 years (range 7-17 years). Mean 
length of aripiprazole usage was 183.4 days. The average start-
ing dosage was 6.1 mg/day [standard deviation (SD) 1.9, range 
5-10], and the mean final dosage was 7.7 mg/day (SD 3.3, range 
5-15). The most common reason for augmentation with aripip-
razole was the lack of target symptom improvement with pre-
vious medication (9 out of 14 children, 64%). In two cases, ari-
piprazole was added due to excessive appetite and weight gain 
while using other atypical antipsychotics (risperidone, olanzapine). 
Response
Ten of 14 patients (71%) showed a reduction in CGI-S scores 
after augmentation with aripiprazole. The CGI-S scores were 
significantly lower at the endpoint than at baseline (5.8±0.8 
to 4.9±1.0, Wilcoxon’s signed rank test: Z=-2.754, p=0.01, ef-
fect size=-0.74). The target symptoms most effectively improv-
ed after using aripiprazole were positive psychotic symptoms 
(mean CGI-I: 2.0±1.4, 3 responders/4 patients, 75% response) 
followed by aggressive behavior (2.5±1.7, 3/4, 75%), self-inju-
rious behavior (2.0±1.0, 2/3, 67%), stereotypic behavior (2.7± 
1.2, 2/3, 67%), tic (2.8±1.0, 2/4, 50%), irritability (3.5±2.1, 1/2, 
50%), hyperactivity (3.4±1.6, 3/7, 43%), obsessive behavior 
(2.5±2.1, 1/3, 33%), and mood fluctuation (3, 0/1, no response). 
A significantly higher mean dosage was found in the resp-
onse group (responders=10.6 mg/day, non-responders=6 
mg/day; t=-2.33, df=12, p=0.04). Five (71%) of seven patients 
with mental retardation and four (57%) of seven patients with-
out mental retardation responded to aripiprazole (Fisher’s exact 
test, p>0.99). Further analysis showed that neither age (t=-0.56, 
df=9, p=0.59) nor duration of treatment (t=-1.33, df=12, p= 
0.21) significantly affected the patients’ responses to the drug. 
Tolerability
At the time of data collection, eight of the 14 (57%) patients 
remained on aripiprazole treatment. Aripiprazole was discon-
tinued in five patients due to unacceptable adverse effects (aka-
thisia, insomnia and withdrawal) and was stopped in one pa-
tient due to target symptom (hyperactivity and tic) improve-
ment. The mean duration of aripiprazole usage until discon-
tinuation was 75.4 days (SD 44.2). Adverse events reported by 
the patients included akathisia (n=2, 14.3%), withdrawal (n=2, 
14.3%), insomnia (n=2, 14.3%), dullness (n=1, 7.1%), increased 
masturbation (n=1, 7.1%), skin rash (n=1, 7.1%), dizziness (n=1, 
7.1%), and vomiting (n=1, 7.1%). 
Aripiprazole and concomitant medication
The response and tolerability of aripiprazole according to the 
concomitant medication was analyzed. Of the seven patients 
using risperidone concomitantly with aripiprazole, five patients 
(71%) showed improvement in CGI-S and three patients (43%) 
discontinued aripiprazole during the trial. For three patients 
using valproic acid or divalproex concomitantly with aripipra-
zole, three patients (100%) showed improvement and one pa-
tient (33%) discontinued aripiprazole. For three patients using 
fluoxetine concomitantly with aripiprazole, three patients (100%) 
showed improvement and one patient (33%) discontinued ari-
piprazole. For three patients using mirtazapine concomitantly 
with aripiprazole, two patients (67%) showed improvement 
while two patients (67%) discontinued aripiprazole. For two 
patients on methylphenidate, one patient (50%) showed impro-
vement while one patient (50%) discontinued the aripiprazole. 
DISCUSSION
The dosage used in this study for augmentative effects was 
7.7 mg/day (range 5-15 mg/day). This is comparable to the dos-
age reported by a 14-week prospective open-label study,
6 which 
reported mean 7.8 mg/day (range: 2.5-15 mg) of aripiprazole 
monotherapy in 25 PDD patients aged 5-17 years. Our find-
ing is also consistent with the results from a retrospective nat-
uralistic study examining 34 PDD patients of 4.5-15 years, 
which reported the mean dosage of 8.1 mg/day.
7
The only open label prospective study published to date, re-
ported no adverse events related to discontinuation of aripipra-
zole.
6 However, other long-term retrospective studies reported 
17-59% discontinuation rates due to adverse effects.
8,9 These 
previously observed adverse events and subsequent discon-
tinuation of monotherapy with aripiprazole are similar to the 
adverse events observed in the present study on augmentation 
with aripiprazole. In the present study, five of fourteen (35.7%) 
children discontinued aripiprazole due to adverse events. Of 
the five patients who discontinued aripiprazole due to adverse 222  Psychiatry Investig 2010;7:220-223
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effects (akathisia and insomnia), three were concomitantly us-
ing psychotropics strongly associated with the release of dopa-
mine (risperidone, ziprasidone, methylphenidate) or with the 
tendency to inhibit cytochrome P450 2D6 and 3A4 enzyme ac-
tivities (fluoxetine), possibly increasing the susceptibility to 
adverse events. A long-term naturalistic evaluations of aripip-
razole monotherapy in children and adolescents reported that 
26-50% of the patients experience adverse events.
7-9 Adverse 
events occurred in 57% (n=8) patients in this study suggesting 
that augmentation use may have similar rate of adverse event. 
The CGI evaluations, although very carefully performed by 
two board-qualified psychiatrists, were conducted retrospec-
tively, allowing a potential source of bias. The weight change 
could not be evaluated due to the concomitant usage of other 
psychotropics. The data, though limited by small sample size 
and naturalistic design, suggest that aripiprazole augmenta-
tion may be done safely for the management of maladaptive 
behaviors in some populations of Asian children with PDD. 
However, future trials are required to confirm these prelimi-
nary findings.
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